Moreover, our data from mouse models and human patient samples demonstrate that high expression of TP63 impedes CD8+ T cell infiltration and tumor killing; inhibition of TP63 enhances the efficacy of PD-1 mAb therapy. The gene discussed is CD8A; the disease is neoplasm.